BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21270261)

  • 1. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
    Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
    Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
    Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
    Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Jung HY; Kim B; Ryu HG; Ji Y; Park S; Choi SH; Lee D; Lee IK; Kim M; Lee YJ; Song W; Lee YH; Choi HJ; Hyun CK; Holzapfel WH; Kim KT
    Diabetes Obes Metab; 2018 Jul; 20(7):1688-1701. PubMed ID: 29516607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
    Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
    Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
    Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
    Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
    Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
    PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
    Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
    J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.
    Ren T; Yang WS; Lin Y; Liu JF; Li Y; Yang LC; Zeng KY; Peng L; Liu YJ; Ye ZH; Luo XM; Ke YJ; Diao Y; Jin X
    Eur J Pharmacol; 2018 May; 826():1-8. PubMed ID: 29476879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice.
    Lee W; Ham J; Kwon HC; Kim YK; Kim SN
    Biochem Biophys Res Commun; 2013 Mar; 432(1):73-9. PubMed ID: 23376064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
    Loza-Rodríguez H; Estrada-Soto S; Alarcón-Aguilar FJ; Huang F; Aquino-Jarquín G; Fortis-Barrera Á; Giacoman-Martínez A; Almanza-Pérez JC
    Eur J Pharmacol; 2020 Sep; 883():173252. PubMed ID: 32534078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance
    Tian Y; Liu Y; Xue C; Wang J; Wang Y; Xu J; Li Z
    Food Funct; 2020 Sep; 11(9):8248-8258. PubMed ID: 32966473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.